How Estrogen Affects Sclerostin Levels in Men and Women
Author Information
Author(s): Mödder Ulrike, Clowes Jackie A, Hoey Kelley, Peterson James M, McCready Louise, Oursler Merry Jo, Riggs B Lawrence, Khosla Sundeep
Primary Institution: Endocrine Research Unit, College of Medicine, Mayo Clinic
Hypothesis
Estrogen treatment reduces circulating sclerostin levels in both postmenopausal women and elderly men.
Conclusion
The study found that estrogen decreases circulating sclerostin levels, which may help explain its role in reducing bone resorption.
Supporting Evidence
- Estrogen treatment in women led to a 27% decrease in serum sclerostin levels.
- In men, estrogen prevented increases in sclerostin levels after sex steroid withdrawal.
- Changes in sclerostin levels correlated with changes in bone-resorption markers.
Takeaway
This study shows that estrogen helps lower a protein called sclerostin, which is important for bone health, in both women and men.
Methodology
The study involved estrogen treatment in postmenopausal women and hormonal manipulation in elderly men to measure changes in sclerostin levels.
Limitations
The study does not clarify whether estrogen directly regulates sclerostin production or if other factors are involved.
Participant Demographics
34 early postmenopausal women aged 40 to 65 years and 59 elderly men aged 50 to 80 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website